Charles River Laboratories International, Inc. (CRL) Shares Bought by Swiss National Bank

Swiss National Bank raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 79,200 shares of the medical research company’s stock after acquiring an additional 900 shares during the quarter. Swiss National Bank owned 0.17% of Charles River Laboratories International worth $8,011,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Eagle Asset Management Inc. lifted its holdings in Charles River Laboratories International by 4.5% in the 2nd quarter. Eagle Asset Management Inc. now owns 305,325 shares of the medical research company’s stock valued at $30,883,000 after acquiring an additional 13,223 shares during the last quarter. Commerce Bank lifted its holdings in Charles River Laboratories International by 4.4% in the 2nd quarter. Commerce Bank now owns 6,558 shares of the medical research company’s stock valued at $663,000 after acquiring an additional 275 shares during the last quarter. Wesbanco Bank Inc. lifted its holdings in Charles River Laboratories International by 45.0% in the 2nd quarter. Wesbanco Bank Inc. now owns 8,483 shares of the medical research company’s stock valued at $858,000 after acquiring an additional 2,634 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Charles River Laboratories International by 4.7% in the 2nd quarter. Principal Financial Group Inc. now owns 198,900 shares of the medical research company’s stock valued at $20,119,000 after acquiring an additional 8,912 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 202 shares during the last quarter. 95.82% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on CRL shares. Credit Suisse Group reissued a “neutral” rating and issued a $95.00 price target (up from $89.00) on shares of Charles River Laboratories International in a report on Tuesday, June 6th. Jefferies Group LLC restated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, June 14th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. Citigroup Inc. restated a “neutral” rating and set a $104.00 price objective (up previously from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. Finally, Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 price objective on the stock in a report on Wednesday, July 12th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories International currently has a consensus rating of “Buy” and an average price target of $98.55.

In other Charles River Laboratories International news, insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total transaction of $643,364.10. Following the transaction, the insider now owns 22,714 shares in the company, valued at $2,442,890.70. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Ross Smith sold 2,552 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the transaction, the insider now owns 11,671 shares in the company, valued at approximately $783,124.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,982 shares of company stock worth $7,951,868. Company insiders own 2.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/15/charles-river-laboratories-international-inc-crl-shares-bought-by-swiss-national-bank.html.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 106.30 on Friday. The firm has a market cap of $5.06 billion, a P/E ratio of 28.01 and a beta of 0.99. The firm’s 50-day moving average price is $102.79 and its 200 day moving average price is $95.17. Charles River Laboratories International, Inc. has a 12-month low of $67.20 and a 12-month high of $109.59.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. During the same quarter last year, the business earned $1.20 earnings per share. The company’s revenue was up 8.1% compared to the same quarter last year. On average, equities analysts expect that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply